Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: Implications for anti-EGFR treatment response

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Boeckx, Carolien ^a   Weyn, Christine ^a   Vanden Bempt, Isabelle ^b   Deschoolmeester, Vanessa ^a   Wouters, An ^a   Specenier, Pol ^c   Van Laer, Carl ^c   Van Den Weyngaert, Danielle ^c   Kockx, Mark ^b   Vermorken, Jan B ^c   Peeters, Marc ^a,c   Pauwels, Patrick ^a,c   Lardon, Filip ^a   Baay, Marc ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HistoGeneX ^*  (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cetuximab; EGFR inhibitors; EGFR tyrosine kinase mutations; EGFRvIII mutations; Head neck squamous cell carcinoma; HPV; KRAS mutations; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PRIMER DNA;

ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; POLYMERASE CHAIN REACTION; VIROLOGY;

ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; FEMALE; GENES, RAS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84903542481     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-337     Document Type: Article

References (38)

1. The stem cell hypothesis in head and neck cancer. Graziano A, d'Aquino R, Tirino V, Desiderio V, Rossi A, Pirozzi G, J Cell Biochem 2008 103 2 408 412 10.1002/jcb.21436 17546610
2. Optimal treatment for recurrent/metastatic head and neck cancer. Vermorken JB, Specenier P, Ann Oncol 2010 21 Suppl 7 22ii252 vii261 20943624
3. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L, J Clin Oncol 2007 25 16 2164 2170 10.1200/JCO.2006.06.6605 17538160
4. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L, Cancer Res 2002 62 24 7350 7356 12499279
5. Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. Murray S, Bobos M, Angouridakis N, Nikolaou A, Linardou H, Razis E, Fountzilas G, J Oncol 2010 2010 709678 21274259
6. Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Dittmann K, Mayer C, Rodemann HP, Strahlenther Onkol 2010 186 1 1 6 10.1007/s00066-009-2026-4 20082181
7. Dysregulated molecular networks in head and neck carcinogenesis. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS, Oral Oncol 2009 45 4-5 324 334 18805044
8. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR, Mol Pharmacol 2008 73 6 1632 1642 10.1124/mol.107.044636 18326051
9. Platinum-based chemotherapy plus cetuximab in head and neck cancer. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R, N Engl J Med 2008 359 11 1116 1127 10.1056/NEJMoa0802656 18784101
10. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, Lardon F, Oncologist 2013 18 7 850 864 10.1634/theoncologist.2013-0013 23821327
11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR, Clin Cancer Res 2006 12 17 5064 5073 10.1158/1078-0432.CCR-06-0913 16951222
12. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P, Cancer Res 2006 66 8 3992 3995 10.1158/0008-5472.CAN-06-0191 16618717
13. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA, N Engl J Med 2004 350 21 2129 2139 10.1056/NEJMoa040938 15118073
14. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M, Science 2004 304 5676 1497 1500 10.1126/science.1099314 15118125
15. The molecular biology of head and neck cancer. Leemans CR, Braakhuis BJ, Brakenhoff RH, Nat Rev Cancer 2011 11 1 9 22 10.1038/nrc2982 21160525
16. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T, Ludkovski O, Wang L, Chen EX, Tsao MS, Kamel-Reid S, Head Neck Oncol 2011 3 11 10.1186/1758-3284-3-11 21352589
17. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Deschoolmeester V, Boeckx C, Baay M, Weyler J, Wuyts W, Van Marck E, Peeters M, Lardon F, Vermorken JB, Br J Cancer 2010 103 10 1627 1636 10.1038/sj.bjc.6605959 20959826
18. A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF, Postmus PE, Meijer CJ, Meijer GA, Snijders PJ, Cell Oncol 2009 31 5 329 333 19759413
19. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ, J Gen Virol 1995 76 Pt 4 1057 1062 9049358
20. A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR. Jacobs MV, van den Brule AJ, Snijders PJ, Helmerhorst TJ, Meijer CJ, Walboomers JM, J Med Virol 1996 49 3 223 229 10.1002/(SICI)1096-9071(199607)49:3<223::AID-JMV11>3.0.CO;2-D 8818969
21. Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. Wachsberger PR, Lawrence RY, Liu Y, Rice B, Daskalakis C, Dicker AP, Front Oncol 2013 3 13 23383403
22. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Greve J, Neyns B, Int J Oncol 2012 41 3 1029 1035 22752145
23. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F, Pauwels P, Peeters M, BMC Cancer 2010 10 189 10.1186/1471-2407-10-189 20459770
24. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G, Zwierzina H, Eur J Cancer 2006 42 1 109 111 10.1016/j.ejca.2005.08.034 16324836
25. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Willmore-Payne C, Holden JA, Layfield LJ, Mod Pathol 2006 19 5 634 640 10.1038/modpathol.3800552 16547470
26. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Szabo B, Nelhubel GA, Karpati A, Kenessey I, Jori B, Szekely C, Petak I, Lotz G, Hegedus Z, Hegedus B, Fule T, Dome B, Timar J, Tovari J, Oral Oncol 2011 47 6 487 496 10.1016/j.oraloncology.2011.03.020 21498106
27. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Hama T, Yuza Y, Saito Y, Ou J, Kondo S, Okabe M, Yamada H, Kato T, Moriyama H, Kurihara S, Urashima M, Oncologist 2009 14 9 900 908 10.1634/theoncologist.2009-0058 19726454
28. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A, Oncogene 2003 22 30 4757 4759 10.1038/sj.onc.1206705 12879021
29. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A, BMC Cancer 2008 8 142 10.1186/1471-2407-8-142 18495026
30. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N, J Mol Diagn 2009 11 2 140 147 10.2353/jmoldx.2009.080100 19213871
31. Human papillomaviruses in head and neck carcinomas. Syrjanen S, N Engl J Med 2007 356 19 1993 1995 10.1056/NEJMe078004 17494934
32. The role of human papillomavirus in oral carcinogenesis. Ha PK, Califano JA, Crit Rev Oral Biol Med 2004 15 4 188 196 10.1177/154411130401500402 15284184
33. Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. Evans M, Newcombe R, Fiander A, Powell J, Rolles M, Thavaraj S, Robinson M, Powell N, BMC Cancer 2013 13 220 10.1186/1471-2407-13-220 23634887
34. Human papillomavirus (HPV) in head and neck cancer. Syrjanen S, J Clin Virol 2005 32 Suppl 1 59 S66 15753013
35. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ, Clin Otolaryngol 2006 31 4 259 266 10.1111/j.1749-4486.2006.01246.x 16911640
36. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, Campisi G, Ann Oncol 2008 19 10 1681 1690 10.1093/annonc/mdn372 18558666
37. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Psyrri A, Sasaki C, Vassilakopoulou M, Dimitriadis G, Rampias T, Head Neck Pathol 2012 6 Suppl 1 121 S128 22782231
38. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, Kraus D, Shah J, Zelefsky M, Pfister D, Lee N, Int J Radiat Oncol Biol Phys 2011 81 4 915 922 10.1016/j.ijrobp.2010.07.008 20947269